Teva Pharmaceutical Industries Ltd. announces new three-year, $1.5 billion unsecured revolving credit facility.
On January 24, Willkie client Teva Pharmaceutical Industries Ltd. announced that it has entered into a new three-year, $1.5 billion unsecured revolving credit facility, which replaces and expands existing credit lines. This facility is part of Teva’s financial strategy to secure liquidity for future business needs through revolving credit lines. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in approximately 60 countries.
In 2010, Willkie advised Teva on its in $2.5 billion offering of senior notes, on the regulatory aspects of its $5 billion acquisition of Ratiopharm GmbH, and on its acquisition of Théramex. The current matter was handled by partner William Hiller and associates Melanie Butcher and Joshua Ndukwe.